target menu

French, Pim

Pim French

Gliomas are the most common type of primary brain tumor (incidence ~1000 patients/year in the Netherlands) with invariably fatal outcome and dismal prognosis. One of the goals of our lab is to identify clinically relevant subgroups of glioma. This line has evolved from discovery screens to validation on randomized phase III clinical trial material. The importance of our work is illustrated by our recent finding that only specific molecular subtypes of glioma benefit from adjuvant PCV chemotherapy. We are currently analyzing material from additional large randomized clinical trials.
The development of novel treatment strategies is required to improve the dismal prognosis of glioma patients. We have therefore developed novel techniques and identified novel causal genetic changes. We have also generated novel model systems (including zebrafish) to study these causal cancer genes. Current efforts are aimed at establishing a facility to support early drug screens and to use next-generation sequencing technology for diagnostic purposes.
Our lab is part of the ErasmusMC Cancer Center and the recently established ‘hersentumorcentrum’ and has strong collaborations with the neuro-oncology clinic, the European Organization for Research and Treatment of Cancer (EORTC) as well as several other (inter-) national collaborations.

Keywords:  Glioma, Omics

1. MGMT-STP27 methylation status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951.
van den Bent MJ, Erdem Eraslan L, Idbaih A, de Rooi JJ, Eilers PH, Spliet W, den Dunnen WF, Tijssen C, Wesseling P, Sillevis Smitt PA, Kros JM, Gorlia T, French PJ. Clin Cancer Res. 2013 Oct 1;19(19):5513-22.

2. Intrinsic Molecular Subtypes of Glioma Are Prognostic and Predict Benefit From Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Combination With Other Prognostic Factors in Anaplastic Oligodendroglial Brain Tumors: A Report From EORTC Study 26951.
Erdem-Eraslan L, Gravendeel LA, de Rooi J, Eilers PHC, Idbaih A, Spliet WGM, den Dunnen WFA, Teepen JL, Wesseling P, Sillevis Smitt PAE, Kros JM, Gorlia T, van den Bent MJ, French PJ. J. Clin Oncol (2013) 31:328-36

3. Somatic mosaic IDH1 orIDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome.
Pansuriya, TC, van Eijk R, de Adamo P, van Ruler M, Kuijjer M, Oosting J, Cleton-Jansen A, van Oosterwijk JG, Verbeke S, Meijer D, van Wezel T, Nord KH, Sangiorgi L, Toker B, Liegl-Atzwanger B, San-Julian M, Sciot R, Limaye N, Kindblom L, Daugaard S, Godfraind C, Boon, LM, Vikkula M, Kurek KC, Szuhai K, French PJ, Bovée JVGM.  Nature genetics (2011) 43:1256-61

4. A Hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.
van den Bent MJ, Gravendeel LA, Gorlia T, Kros JM, Lapre L, Wesseling P, Teepen JL, Adbaih A, Sanson M, Sillevis Smitt PAE, French PJ. Clin Can Res (2011); 17:1748-55 

5. The CASPR2 cell adhesion molecule functions as a tumor suppressor gene in glioma.
Bralten LB, Gravendeel AM, Kloosterhof NK, Sacchetti A, Vrijenhoek T, Veltman JA, van den Bent MJ, Kros JM, Hoogenraad CC, Sillevis Smitt PA, French PJ. Oncogene. (2010); 29:6138-48

6. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology.
Gravendeel LA, Kouwenhoven MC, Gevaert O, de Rooi JJ, Stubbs AP, Duijm JE,  Daemen A, Bleeker FE, Bralten LB, Kloosterhof NK, De Moor B, Eilers PH, van der Spek PJ, Kros JM, Sillevis Smitt PA, van den Bent MJ, French PJ. Cancer Res. 2009 Dec 1;69(23):9065-72.